{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:05:45Z","timestamp":1789563945853,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,13]],"date-time":"2027-08-13T00:00:00Z","timestamp":1818115200000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R01AI139261"],"award-info":[{"award-number":["R01AI139261"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jchromb.2026.125249","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:38:22Z","timestamp":1786405102000},"page":"125249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of a novel LC-MS\/MS method for simultaneous quantification of fidaxomicin and metabolite (OP-1118) from feces for gut pharmacobiome studies"],"prefix":"10.1016","volume":"1282","author":[{"given":"Chenlin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Eubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian G.","family":"Hurdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Garey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125249_bb0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.jchromb.2026.125249_bb0010","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","article-title":"Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection","volume":"55","author":"Sears","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jchromb.2026.125249_bb0015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2026.125249_bb0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.jchromb.2026.125249_bb0025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/jac\/dkz549","article-title":"Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial","volume":"75","author":"Guery","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2026.125249_bb0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5414\/CP204263","article-title":"Pharmacokinetic evaluation and relative bioavailability pilot study of fidaxomicin in healthy Chinese subjects: an open, randomized, single-dose, cross-over study","volume":"60","author":"Cao","year":"2022","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.125249_bb0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40261-015-0291-9","article-title":"Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects","volume":"35","author":"Oshima","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jchromb.2026.125249_bb0040","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/AAC.02590-15","article-title":"Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice","volume":"60","author":"Deshpande","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2026.125249_bb0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tifs.2016.05.011","article-title":"Metabolomics of fecal samples: a practical consideration","volume":"57","author":"Matysik","year":"2016","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.jchromb.2026.125249_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2018.05.031","article-title":"A review on human fecal metabolomics: methods, applications and the human fecal metabolome database","volume":"1030","author":"Karu","year":"2018","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2026.125249_bb0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/infdis\/jiad537","article-title":"Fecal pharmacokinetics and gut microbiome effects of Oral Omadacycline versus vancomycin in healthy volunteers","volume":"229","author":"Jo","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jchromb.2026.125249_bb0060","series-title":"M10 BIOANALYTICAL METHOD VALIDATION AND STUDY SAMPLE ANALYSIS: guidance for industry U.S. Food and Drug Administration","author":"FDA","year":"2022"},{"key":"10.1016\/j.jchromb.2026.125249_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01259-19","article-title":"Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016","volume":"63","author":"Aoki","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2026.125249_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124057","article-title":"Development and validation of LC-MS\/MS for quantifying omadacycline from stool for gut microbiome studies","volume":"1236","author":"Hu","year":"2024","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2026.125249_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2026.125249_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01688-21","article-title":"A vancomycin HPLC assay for use in gut microbiome research","volume":"10","author":"Hu","year":"2022","journal-title":"Microbiol. Spectrum"},{"key":"10.1016\/j.jchromb.2026.125249_bb0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpba.2007.12.019","article-title":"Beyond pass\/fail: a procedure for evaluating the effect of carryover in bioanalytical LC\/MS\/MS methods","volume":"47","author":"Clouser-Roche","year":"2008","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:22:54Z","timestamp":1789561374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226003387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"alternative-id":["S1570023226003387"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125249","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a novel LC-MS\/MS method for simultaneous quantification of fidaxomicin and metabolite (OP-1118) from feces for gut pharmacobiome studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125249"}}